Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2019

Filed with the SEC on Aug 7, 2019 and accepted by EDGAR at Aug 7, 2019, 16:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-04-01 to 2019-06-30$715.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2019-01-01 to 2019-06-30$2.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2019-04-01 to 2019-06-30$10.1mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2019-01-01 to 2019-06-30$21.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2019-04-01 to 2019-06-30−$12.3mus-gaap:OperatingIncomeLoss
Operating income6 months2019-01-01 to 2019-06-30−$30.2mus-gaap:OperatingIncomeLoss
Net income3 months2019-04-01 to 2019-06-30−$11.8mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income6 months2019-01-01 to 2019-06-30−$29.0mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2019-04-01 to 2019-06-30−$0.84us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2019-01-01 to 2019-06-30−$2.21us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2019-01-01 to 2019-06-30−$24.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2019-01-01 to 2019-06-30$484.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-06-30$19.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-06-30$84.4mus-gaap:AssetsCurrent
Total assetsAt period end2019-06-30$142.2mus-gaap:Assets
Current liabilitiesAt period end2019-06-30$11.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-06-30$32.6mus-gaap:Liabilities
Shareholders' equityAt period end2019-06-30$109.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-19-044531. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.